Izliah Grace Nicole Lonzame Fabian

Ms. Izliah Grace Nicole Lonzame Fabian

Biomedical, Manufacturing, Robotics Engineering, De La Salle University, Manila, Philippines
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RBRaneille Quirsten Baligod
Raneille Quirsten Baligod
IFIzliah Grace Nicole Lonzame Fabian
Izliah Grace Nicole Lonzame Fabian
KRKristine Margreth Bagarinao Repol
Kristine Margreth Bagarinao Repol
HSHeidi Lindt Sy
Heidi Lindt Sy
JMJubert Marquez
Jubert Marquez
JAJoseph Rey Sta. Agueda
Joseph Rey Sta. Agueda
Diabetic foot ulcers (DFUs) affect 19–34% of diabetic patients with a five-year mortality rate of 50–70%. It is characterized by a high infection risk, chronic inflammation, oxidative stress, and poor angiogenesis, rendering existing therapies inadequate, which causes antimicrobial resistance and amputations. Bioactive compounds, such as curcumin, flavonoids, tannins, polyphenols, and proteins, found in natural product extracts (NPEs) have antibacterial, anti-inflammatory, antioxidant, and regenerative properties but are prone to variability and instability. Conventional drugs can be applied for targeted infection management and metabolic modulation, but lack regenerative capacity. The combined and synergistic potential of these two agents has not received much attention, especially when integrated into advanced drug delivery systems (DDSs), such as microneedles, hydrogels, nanofibers, and smart bandages. This review discusses NPEs, conventional drugs, combinations, and integration into DDSs, based on wound characteristics. These include depth, infection status, exudate level, and perfusion, as recommended by the 2023 IWGDF guidelines. Three combinations have shown promise in preclinical studies: propolis-charcoal bandages, propolis-oregano microneedles, and Centella-ZnO nanocomposites. However, none have yet been validated in clinical settings, and barriers to clinical adoption persist—standardization, stability, and regulatory issues. This work aims to pave the way for more accessible, sustainable, and efficacious DFU therapeutics by bridging natural and conventional approaches.